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The 2011 Cicatricial Alopecia Sympo-
sium* was attended by approximately
90 members of the scientific community
representing academia, industry, and gov-
ernment. The program was held over 2
days and included three keynote talks and
six sessions: (i) Bench: ‘‘Mechanisms of
inflammation’’; (ii) Bedside: ‘‘Disease Pre-
sentation and Epidemiology’’; (iii) Bench:
‘‘Nuclear Receptors and Lipids in Skin
and Hair Disease’’; (iv) Bedside: ‘‘Current
and Emerging Therapies for Cicatricial
Alopecia’’; (v) Identifying Translational
Opportunities in Cicatricial Alopecia;
and (vi) Stem cells, Cicatricial Alopecia,
and Hair Follicle Regeneration. In addi-
tion to major talks by invited speakers, the
meeting included short talks selected from
submitted abstracts, followed by panel
discussions. The symposium culminated
in a workshop composed of small discus-
sion groups, each focusing on specific
research questions and priorities.
Dr Stephen I Katz (NIAMS) discussed
new directions at NIAMS and said that
funding for hair research has steadily
increased over the past 10 years. The
symposium began with keynote
addresses by David Norris (University
of Colorado School of Medicine) and
Frederick Miller (Environmental Autoim-
munity Group, NIEHS). Dr Norris gave
an overview of inflammatory alopecia
and noted that alopecia areata and
primary cicatricial alopecia (PCA) are
the yin and yang of hair disorders. The
inflammatory infiltrate targets the hair
follicle (HF) bulb and spares the bulge
stem cells in alopecia areata, whereas it
targets the permanent, stem cell portion
of the follicle in PCA, thereby making
the hair loss permanent. He pointed out
that factors driving the inflammatory
reactions in PCA are poorly defined.
He emphasized the recent associations
reported in laboratory models of lipid
abnormalities and hair loss. He noted
that defined targets, such as peroxisome
proliferator-activated receptor gamma
(PPARg) involvement in lichen planopi-
laris pathogenesis and treatment, have
yet to be found in alopecia areata.
Dr Miller gave an overview of the role
of environment in the pathogenesis of
autoimmune diseases and emphasized
the role of UV radiation in autoimmune
diseases, which induces greater skin
inflammation in female mice compared
with male mice. His take-home message
was that major risk factors for autoim-
mune diseases are both environmental
and genetic, and that there is a clear
gender bias in the prevalence of anti-
nuclear antibodies and in the expression
of estrogen and IFN-responsive genes.
He suggested that it might be important
to evaluate the incidence of each of the
PCA subtypes in different parts of the
world.
Mechanisms of inflammation
John Ortaldo (Laboratory of Experimen-
tal Immunology, NCI) discussed the
distinct features of natural killer and
natural killer T cells, the pattern of their
cytokine profiles, their activation, and
their role in bridging the innate and
adaptive immune responses. He noted
that in the alopecia studies reported to
date, there was little discrimination
made between natural killer and natural
killer T cells. Francisco Quintana
(Harvard Medical School) showed that
the interaction of Aryl-hydrocarbon
receptor (AhR) with c-Maf is essential
for the generation of mouse and human
IL-10-secreting type 1 regulatory T cells
that suppress inflammatory responses.
His take-home message was that the
in vivo immunological effects of AhR
activation are tissue and ligand specific,
and that in autoimmune disease, the
outcome likely depends on the type of
T-cell differentiation pathway activated
by a given AhR ligand.
Matt Harries (University of Manches-
ter) provided an overview of the HF,
bulge stem cells, and the HF’s immune
privilege and how the immune proper-
ties of the HF are altered in lesional
lichen planopilaris tissue. John Harris
(University of Massachusetts) suggested
a new method for approaching autoim-
mune diseases for the purposes of clin-
ical treatment, drug development, and
determination of pathogenesis based on
cytokine profiles, clinical presentation,
signs and symptoms, pathology, and
epidemiology. He noted that diseases
with similar profiles may respond to
similar therapies.
Disease presentation and epidemiology
Vera Price (University of California, San
Francisco) discussed the NAHRS classi-
fication of cicatricial alopecia, the
demographics of patients, and the clin-
ical features of the different subtypes of
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PCA. Len Sperling (Uniformed Services
University) spoke of the controversy in
the identification of different cicatricial
alopecia subtypes and discussed an
alternate classification for the disease.
He suggested five fairly distinct types
of cicatricial alopecia: (1) chronic cuta-
neous lupus erythematosus (discoid LE);
(2) lichen planopilaris; (3) dissecting
cellulitis (perifolliculitis abscedens et
suffodiens); (4) acne keloidalis; and (5)
central centrifugal scarring alopecia
(follicular degeneration syndrome, folli-
culitis decalvans, pseudopelade). Elise
Olsen (Duke University Medical Center)
discussed the incidence, potential risk
factors, and a new photographic scale
for exploring etiological factors in central
hair loss in African-American women.
Nuclear receptors and lipids in skin and
hair disease
Beatrice Desvergne (University of Lau-
sanne, Switzerland) described a global
knockout mouse model of PPARg that
shows disrupted HFs, lack of sebaceous
glands, and absent subcutaneous fat.
Starting at postnatal day 28, HF disrup-
tion, massive inflammatory infiltration,
and scarring were observed. Bret Evers
(University of Texas Southwestern Med-
ical Center) described hair growth
defects in an insulin-induced gene 1
(Insig1)-deficient mouse model. The
mice displayed defects in postnatal HF
cycling because of cholesterol precursor
accumulation that could be rescued
after treatment with Simvastatin.
Pratima Karnik (Case Western Reserve
University) presented gene expression
profiles of lymphocytic and neutrophilic
PCA to show that lipid metabolic
changes are a hallmark of all PCA
subtypes and that altered lipids underlie
the pathogenesis of this group of alope-
cia. She emphasized the central role of
PPARg and other nuclear receptors in
the pathogenesis of PCA. PPARg is a
transcription factor that belongs to the
nuclear receptor family and has emer-
ged as an important regulator of lipid
metabolic and inflammatory genes. Dr
Karnik presented data from the PPARg
knockout and AhR transgenic mouse
models of scarring alopecia to demon-
strate that lipid metabolic changes pre-
cede inflammatory changes and are
caused by altered PPARg signaling in
HFs and sebaceous glands.
Current and emerging therapies for
cicatricial alopecia
Jerry Shapiro (New York University, Uni-
versity of British Columbia) reviewed the
current treatments for cicatricial alopecia
and outlined how he would treat each
subtype. Paradi Mirmirani (The Perma-
nente Medical Group) discussed emerging
therapies, including her experience in
treating lichen planopilaris patients with
Pioglitazone (a PPARg agonist).
Dr Mirmirani reported that 50% of the
patients responded to the treatment as
determined by reduced inflammatory
cells on hematoxylin and eosin sections
and by a reduction in clinical itch and
inflammation. Dr Wilma Bergfeld (The
Cleveland Clinic Foundation) described
her experience with Pioglitazone and
reported a positive response in 67%
of treated patients, with resultant hair
regrowth in two of the patients. Because
of the reported incidence of bladder
cancer in rodents on systemic therapy,
topical treatment with Pioglitazone was
discussed as a possible alternative to
oral treatment. John Varga (Northwes-
tern University) reported that PPARg
expression and activity is decreased in
scleroderma patients with early-stage
disease and that this correlates inversely
with skin fibrosis. His studies showed
that treatment of mice with bortezomib,
a proteosomal inhibitor, resulted in
upregulation of tissue PPARg and resis-
tance to bleomycin-induced skin and
lung fibrosis. Dr Varga pointed out that
scleroderma and PCA have common
histopathological features and a shared
pathomechanism—that is, a defect in
local PPARg function. These intriguing
commonalities point to the possibility
of common therapeutic approaches for
these two disparate conditions.
The Dinner Speaker on Day 1 was
Jean-Hilaire Saurat (University of Geneva,
Switzerland). Dr Saurat reviewed the
effects of high doses of dioxin on the skin
of his patients. Although toxic doses of
dioxin did not cause clinical hair loss,
they did result in histological loss of
sebaceous glands and formation of cystic
hamartomas. He emphasized the need
for new biomarkers of dioxin toxicity.
The second day began with a keynote
talk by Christopher Austin (NIH Center for
Translational Therapeutics) who defined
rare and neglected diseases and gave an
overview of the congressionally man-
dated program to speed the development
of new drugs for these diseases. He cited
specific examples of successful collabora-
tions between the NIH Therapeutics for
Rare and Neglected Diseases program,
big pharma, biotechnology companies,
and universities.
Identifying translational opportunities in
cicatricial alopecia
Donna Mendrick (National Center for
Toxicological Research, FDA) empha-
sized the need for new biomarkers of
disease diagnosis and drug efficacy. She
suggested that, to enable their use in the
clinic, noninvasive biomarkers in body
fluids and bioimaging are needed. David
Margolis (University of Pennsylvania)
explained the differences between com-
parative effectiveness (use in general
practice) and comparative efficacy (use
in an ideal setting), and discussed meth-
ods to conduct comparative effective-
ness research. He said that as PCA is a
rare disease, the study population and
disease population may be largely the
same. His suggestion was to prove effec-
tiveness in the basic population and thus
define who to treat and how to use obser-
vational, proof-of-concept, and transla-
tional studies.
Stem cells, cicatricial alopecia, and HF
regeneration
Luis Garza (Johns Hopkins University
School of Medicine) described a role for
prostaglandin D2 and its receptor DP-2
in the development of androgenetic
alopecia, thereby providing another
lipid-based target as a hair loss treat-
ment. Isaac Brownell (NCI, NIH)
described studies to show that Sonic
hedgehog secreted by sensory neurons
signals to a population of cells in the
telogen bulge marked by the Hedgehog
response gene Gli1.The perineural stem
cell niche is necessary to maintain bulge
cells capable of becoming epidermal
stem cells but, interestingly, is dispensa-
ble for follicle contributions to acute
wound healing and hair homeostasis.
George Cotsarelis (University of Pennsyl-
vania) discussed the role of HF bulge
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stem cells in wound healing. He sug-
gested that understanding the regenera-
tion of HFs after wounding is the first step
toward developing new treatments for
scarring alopecias.
Workshop and breakout sessions
David Norris, Kevin D Cooper, Matt
Harries, John Harris, and Francisco Quin-
tana led discussions on ‘‘Mechanisms of
Inflammation’’. Vera Price, Elise Olsen,
Paradi Mirmirani, Amy McMichael led
discussions on ‘‘Clinical Aspects, Disease
Presentation and Epidemiology.’’ Pratima
Karnik, Bret Evers, Lloyd King, Beatrice
Desvergne led the discussions on ‘‘Envir-
onmental Influences, Nuclear Receptors
and Lipids.’’ George Cotsarelis, Kurt
Stenn, Isaac Brownell, Ken Washenik
led the discussions on ‘‘Stem Cells and
Hair Follicle Regeneration’’.
Several themes became apparent
from these discussions. One theme dealt
with classification: Do the PCAs repre-
sent one or a family of disorders with
different etiologies and pathogenetic
mechanisms? Although the histology of
these diseases suggests some common-
ality, the clinical presentations suggest
differences. A second theme focused on
the role of immunity and inflammation
during the course of the disease. Is the
inflammatory reaction primary or sec-
ondary? How much of the inflammatory
reaction reflects an autoimmune pro-
cess? It was generally believed that the
argument for a strong autoimmune com-
ponent has not yet been put forth,
although that possibility has not been
entirely excluded. A third theme was the
novel association of lipid pathways in
hair biology. Most attendees were influ-
enced by the generally unrecognized
impact that lipid pathways and the
sebaceous gland have in the normal
health of the HF, as well their role in
the pathogenesis of several laboratory
models and clinical systems. The
description of lipid metabolic pathways,
such as the PPARg target genes, sterol
intermediates in PCA, and prostaglan-
dins in lichen planopilaris and androge-
netic alopecia, was most insightful.
Current evidence suggests that the
sebaceous gland in the PPARg knockout
and AhR transgenic mouse models dis-
appears before the infiltration of inflam-
matory infiltrate. This observation raises
several questions. Is it that the sebaceous
gland is highly sensitive to the destruc-
tive etiologic agent, or does the loss of
the sebaceous gland cause the loss of
HFs? What is the role of the sebaceous
gland in hair biology, anyway? The data
presented suggesting some role for
PPARg and AhR in these disorders are,
at present, compelling and cannot be
easily be disregarded. In fact, the action
of these molecules at this time offers the
best mechanistic explanation, and per-
haps the best therapeutic targets.
Marked progress has been made in
this field since the last NIH Colloquium
(October 2005). In the future and in
subsequent meetings, we hope certain
projects will be tackled. (1) We need a
more extensive record of PCA patients
with family and environmental his-
tories, by initiating a central database
that physicians around the world can
contribute to and utilize. (2) We need
better definition of each of the PCA
entities by differentiating the time
course of the disease at all levels and
some definition of the conditions asso-
ciated with the onset. (3) We need a
direct and focused attempt to elucidate
the role of the sebaceous gland in hair
biology by, for example, using such
tools as conditional sebaceous gland
knockout models. (4) Finally, we need
a greater understanding of the role of
lipids in the pathogenesis of these dis-
ease, and in particular, aggressive dis-
section of the PPARg signaling pathway
and the potential role it might have in
the development of each of the sundry
PCA presentations. Much needs to be
done, but the future looks surprisingly
bright regarding a confident understand-
ing of and effective treatments for this
long neglected group of hair disorders.
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*The Cicatricial Alopecia Symposium 2011, ‘‘Lipids,
Inflammation and Stem Cells,’’ was held in Bethesda,
Maryland, USA, 27–28 October 2011. Information
about the content and support of the symposium can
be found at http://www.cicatricialalopecia.org.
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